Literature DB >> 23103610

Obesity pharmacotherapy: what is next?

Francheska Colon-Gonzalez1, Gilbert W Kim, Jieru E Lin, Michael A Valentino, Scott A Waldman.   

Abstract

The increase in obesity in the Unites States and around the world in the last decade is overwhelming. The number of overweight adults in the world surpassed 1 billion in 2008. Health hazards associated with obesity are serious and include heart disease, sleep apnea, diabetes, and cancer. Although lifestyle modifications are the most straightforward way to control weight, a large portion of the population may not be able to rely on this modality alone. Thus, the development of anti-obesity therapeutics represents a major unmet medical need. Historically, anti-obesity pharmacotherapies have been unsafe and minimally efficacious. A better understanding of the biology of appetite and metabolism provides an opportunity to develop drugs that may offer safer and more effective alternatives for weight management. This review discusses drugs that are currently on the market and in development as anti-obesity therapeutics based on their target and mechanism of action. It should serve as a roadmap to establish expectations for the near future for anti-obesity drug development.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23103610      PMCID: PMC4076900          DOI: 10.1016/j.mam.2012.10.005

Source DB:  PubMed          Journal:  Mol Aspects Med        ISSN: 0098-2997


  107 in total

1.  Amylin concentrations and glucose control.

Authors:  J E Koda; M Fineman; T J Rink; G E Dailey; D B Muchmore; L G Linarelli
Journal:  Lancet       Date:  1992-05-09       Impact factor: 79.321

2.  Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum.

Authors:  R Mentlein; B Gallwitz; W E Schmidt
Journal:  Eur J Biochem       Date:  1993-06-15

Review 3.  Biological actions of cholecystokinin.

Authors:  J N Crawley; R L Corwin
Journal:  Peptides       Date:  1994       Impact factor: 3.750

Review 4.  Molecular physiology of amylin.

Authors:  R A Pittner; K Albrandt; K Beaumont; L S Gaeta; J E Koda; C X Moore; J Rittenhouse; T J Rink
Journal:  J Cell Biochem       Date:  1994       Impact factor: 4.429

5.  Serum immunoreactive-leptin concentrations in normal-weight and obese humans.

Authors:  R V Considine; M K Sinha; M L Heiman; A Kriauciunas; T W Stephens; M R Nyce; J P Ohannesian; C C Marco; L J McKee; T L Bauer
Journal:  N Engl J Med       Date:  1996-02-01       Impact factor: 91.245

6.  A role for glucagon-like peptide-1 in the central regulation of feeding.

Authors:  M D Turton; D O'Shea; I Gunn; S A Beak; C M Edwards; K Meeran; S J Choi; G M Taylor; M M Heath; P D Lambert; J P Wilding; D M Smith; M A Ghatei; J Herbert; S R Bloom
Journal:  Nature       Date:  1996-01-04       Impact factor: 49.962

7.  Specificity of leptin action on elevated blood glucose levels and hypothalamic neuropeptide Y gene expression in ob/ob mice.

Authors:  M W Schwartz; D G Baskin; T R Bukowski; J L Kuijper; D Foster; G Lasser; D E Prunkard; D Porte; S C Woods; R J Seeley; D S Weigle
Journal:  Diabetes       Date:  1996-04       Impact factor: 9.461

8.  Pylorectomy reduces the satiety action of cholecystokinin.

Authors:  T H Moran; L Shnayder; A M Hostetler; P R McHugh
Journal:  Am J Physiol       Date:  1988-12

9.  The role of neuropeptide Y in the antiobesity action of the obese gene product.

Authors:  T W Stephens; M Basinski; P K Bristow; J M Bue-Valleskey; S G Burgett; L Craft; J Hale; J Hoffmann; H M Hsiung; A Kriauciunas
Journal:  Nature       Date:  1995-10-12       Impact factor: 49.962

10.  Gene duplication of the human peptide YY gene (PYY) generated the pancreatic polypeptide gene (PPY) on chromosome 17q21.1.

Authors:  Y Hort; E Baker; G R Sutherland; J Shine; H Herzog
Journal:  Genomics       Date:  1995-03-01       Impact factor: 5.736

View more
  16 in total

Review 1.  Obesity: Current and potential pharmacotherapeutics and targets.

Authors:  Vidya Narayanaswami; Linda P Dwoskin
Journal:  Pharmacol Ther       Date:  2016-10-20       Impact factor: 12.310

2.  Intranasal delivery of N-terminal modified leptin-pluronic conjugate for treatment of obesity.

Authors:  Dongfen Yuan; Xiang Yi; Yuling Zhao; Chi-Duen Poon; Kristin M Bullock; Kim M Hansen; Therese S Salameh; Susan A Farr; William A Banks; Alexander V Kabanov
Journal:  J Control Release       Date:  2017-03-24       Impact factor: 9.776

Review 3.  Neurochemical regulators of food behavior for pharmacological treatment of obesity: current status and future prospects.

Authors:  Gayane Sargis Vardanyan; Hasmik Samvel Harutyunyan; Michail Iosif Aghajanov; Ruben Sargis Vardanyan
Journal:  Future Med Chem       Date:  2020-10-12       Impact factor: 3.808

Review 4.  Future Pharmacotherapy for Obesity: New Anti-obesity Drugs on the Horizon.

Authors:  Gitanjali Srivastava; Caroline Apovian
Journal:  Curr Obes Rep       Date:  2018-06

5.  Pharmacophore-based virtual screening from phytocannabinoids as antagonist r-CB1.

Authors:  Lenir C Correia; Jaderson V Ferreira; Henrique B de Lima; Guilherme M Silva; Carlos H T P da Silva; Fábio A de Molfetta; Lorane I S Hage-Melim
Journal:  J Mol Model       Date:  2022-08-17       Impact factor: 2.172

Review 6.  The genus Rumex (Polygonaceae): an ethnobotanical, phytochemical and pharmacological review.

Authors:  Jing-Juan Li; Yong-Xiang Li; Na Li; Hong-Tao Zhu; Dong Wang; Ying-Jun Zhang
Journal:  Nat Prod Bioprospect       Date:  2022-06-16

7.  Myricetin protects against diet-induced obesity and ameliorates oxidative stress in C57BL/6 mice.

Authors:  Hong-Ming Su; Li-Na Feng; Xiao-Dong Zheng; Wei Chen
Journal:  J Zhejiang Univ Sci B       Date:  2016-06       Impact factor: 3.066

Review 8.  Brain delivery of proteins via their fatty acid and block copolymer modifications.

Authors:  Xiang Yi; Alexander V Kabanov
Journal:  J Drug Target       Date:  2013-12       Impact factor: 5.121

9.  Effects of a leucine and pyridoxine-containing nutraceutical on body weight and composition in obese subjects.

Authors:  Michael B Zemel; Antje Bruckbauer
Journal:  Diabetes Metab Syndr Obes       Date:  2013-08-23       Impact factor: 3.168

Review 10.  Targeting Energy Expenditure-Drugs for Obesity Treatment.

Authors:  Carlos M Jimenez-Munoz; Marta López; Fernando Albericio; Kamil Makowski
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.